News / Taiwan / economic_daily
Bora Pharmaceuticals Hits Record Monthly Revenue of NT$2.33 Billion in September
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-10-11
1271, 6472
Bora Pharmaceuticals reported a record-breaking September revenue of NT$2.33 billion, marking a 35.13% year-over-year increase driven by strong CDMO demand.
What Happened
Revenue Performance: Bora Pharmaceuticals achieved a record-breaking consolidated revenue of NT$2.33 billion in September, representing a 35.13% year-over-year growth. For the first nine months of the year, cumulative revenue reached NT$163.04 billion, reflecting a steady upward trend in operational momentum.
Capacity Management: Despite scheduled maintenance at the Maryland sterile injectable facility, high utilization rates at the Canadian and Zhunan plants successfully offset the production gap. The company’s cross-facility scheduling and supply chain efficiency have effectively mitigated the impact of individual site fluctuations.
Strategic Diversification: Revenue was bolstered by asset divestitures and the peak retail season for the subsidiary Weider Global Nutrition. Additionally, the acquisition of a new ophthalmic drug approval by Upsher-Smith has further strengthened the company's product portfolio in the U.S. market.
Future Outlook: With the fourth-quarter peak season approaching for both pharmaceuticals and retail, the dual engines of CDMO services and global drug sales are expected to drive continued synergy. Bora remains focused on leveraging its global platform to maintain operational resilience through specialized medicine and consumer health products.